M&A Deal Summary |
|
|---|---|
| Date | 2017-10-26 |
| Target | Neos Therapeutics |
| Sector | Life Science |
| Buyer(s) | PDL BioPharma |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Jefferies (Financial) Goodwin Procter (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 109 |
| Revenue | 55M USD (2019) |
PDL BioPharma is a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL BioPharma was founded in 1986 and is based in Incline Village, Nevada.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Texas M&A | 1 of 1 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-04 |
Depomed - Diabetes Royalty Rights
United States Depomed - Diabetes Royalty Rights is a provider of medical products. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-09 |
Noden Pharma DAC
Dublin, Ireland Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market, and sell Tekturna® and Tekturna HCT (or Rasilez and Rasilez HTC outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg, and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland. |
Sell | $53M |
